Every drug approved in the United States passes through a deadline nobody voted on and almost nobody outside biotech has heard of: the PDUFA date. Named for the 1992 Prescription Drug User Fee Act, it's the day by which the FDA has committed to render a decision — approve, reject, or ask for more data — on a pending drug application. That single administrative deadline is the most reliable, most repeatable volatility event in the entire stock market. It is scheduled in advance, it is public, and it still routinely moves single-name biotech stocks 30-80% in one session.
This is the purest form of a policy-to-profit mechanism: a piece of federal law forces a federal agency to answer a yes-or-no question on a specific calendar day, and the answer instantly reprices a company's entire reason for existing. Unlike a Fed rate decision or a tariff announcement, which move a basket of companies by a few percent, a PDUFA date moves one company by an enormous amount, because for a single-asset biotech the drug often is the company. Understanding how this calendar works — and who sits around the edges of the binary event rather than inside it — is a durable skill for reading the sector, not a one-time trade.
This guide explains the mechanism, names the real players who profit from the PDUFA system whether or not any single drug gets approved, and gives you a concrete way to find and track these dates yourself.